Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Preliminary phase II data show activity of quizartinib in FLT3-ITD+ AML

June 20, 2011

Data presented from two phase II trials of BCX-4208 with/without allopurinol in gout

June 17, 2011

BMT-4-159 is a new 17-beta-HSD 5 inhibitor with potential to treat prostate cancer

June 17, 2011

Pilot study supports tolerability of AC-480 in patients with recurrent malignant glioma

June 17, 2011

Phase II ARQ-197 trial assesses safety and efficacy in relapsed/refractory non-CNS germ cell tumors

June 17, 2011

Phase II extension trial evaluates continued E-5501 treatment of thrombocytopenia

June 17, 2011

GlaxoSmithKline discloses first-in-human data on GSK-2126458 and GSK-2141795

June 17, 2011

Lithostathine-1-alpha as a new biomarker in rheumatoid arthritis

June 16, 2011

Veliparib/temozolomide combination is safe in metastatic unresectable CRC

June 16, 2011

Phase I/II data on navitoclax in lymphoid malignancies updated

June 16, 2011

Popular Stories

Today's news in brief
BioWorld
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...